Form 4: Castellum Director Granted 100,000 Stock Options

Castellum, Inc. director Charles Thomas McMillen received 100,000 stock options as compensation, vesting over 20 months.

Summary

• Charles Thomas McMillen, a Director of Castellum, Inc. (CTM), was granted 100,000 stock options.
• The options have an exercise price of $1.19 per share.
• The grant date was November 11, 2025, and the options expire on November 10, 2032.
• These options were issued as compensation for his service as an independent Board member.
• The options will vest ratably over a period of twenty months, starting December 1, 2025.

Sentiment

Score: 7

Explanation: The filing indicates a standard compensation practice for a director, aligning interests with shareholders, which is generally positive for corporate governance and stability. No negative surprises or significant financial impacts are immediately apparent.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term performance.
• The options serve as compensation for the director's service, indicating continued commitment to the company's governance.

Negatives

• The issuance of stock options could lead to dilution if exercised, though this is a common form of executive compensation.

Future Outlook

The vesting schedule extending to 2027 (20 months from December 1, 2025) suggests a long-term commitment from the director and an expectation of continued service and value creation over this period.

Industry Context

Granting stock options to independent directors is a standard practice across many industries, particularly in technology and growth-oriented companies, to align director incentives with shareholder value creation and retain experienced board members.

Comparison to Industry Standards

• The grant of 100,000 stock options to an independent director with an exercise price of $1.19 and a 7-year expiration (from grant date) is within the typical range for director compensation in small to mid-cap companies, especially those in the technology or government contracting sectors like Castellum.
• The 20-month ratable vesting schedule is also a common mechanism to ensure continued service and long-term alignment, comparable to practices seen at companies like SAIC or CACI International for their non-executive directors, though the specific number of options and vesting period can vary based on company size, stock price, and compensation philosophy.

Corporate Governance

Related Party Transactions

• The transaction involves the grant of stock options to a director, Charles Thomas McMillen, which constitutes a related party transaction. This is a standard and disclosed form of compensation for board service.

Stakeholder Impact

• Shareholders: Potential minor dilution upon exercise, but also improved alignment of director interests with shareholder value.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Next Steps

• The options will begin vesting ratably over twenty months starting December 1, 2025.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction related to director compensation. It does not contain information that would fundamentally alter the investment thesis for Castellum, Inc. The grant of options aligns the director's interests with shareholders, which is a positive for governance, but it's not a catalyst for a "buy" or "sell" recommendation. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Castellum, CTM, Form 4, stock options, insider transaction, director compensation, equity grant, beneficial ownership, corporate governance